There has been a real interest recently in developing once-daily beta(2)-adrenoceptor agonists (ultra-long-acting beta(2)-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic obstructive pulmonary disease (COPD) in an attempt to simplify their management, although an increasing amount of convincing data show an association of LABAs with a rise in asthma-related deaths and life-threatening experiences. This paper reviews the effects of different ultra-LABAs that are at varying stages of development. Arformoterol, carmoterol, indacaterol and GSK-159797 are ultra-LABAs that are likely to be introduced into the market before 2010. It is plausible that once-daily dose administration of an LABA will lead to increased convenience for patients, which may also lead to enhancement of adherence, and may have advantages leading to improved overall clinical outcomes in patients with asthma and COPD.

Matera, M.G., & Cazzola, M. (2007). Ultra-long-acting beta(2)-adrenoceptor agonists - An emerging therapeutic option for asthma and COPD?. DRUGS, 67(4), 503-515 [10.2165/00003495-200767040-00002].

Ultra-long-acting beta(2)-adrenoceptor agonists - An emerging therapeutic option for asthma and COPD?

CAZZOLA, MARIO
2007

Abstract

There has been a real interest recently in developing once-daily beta(2)-adrenoceptor agonists (ultra-long-acting beta(2)-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic obstructive pulmonary disease (COPD) in an attempt to simplify their management, although an increasing amount of convincing data show an association of LABAs with a rise in asthma-related deaths and life-threatening experiences. This paper reviews the effects of different ultra-LABAs that are at varying stages of development. Arformoterol, carmoterol, indacaterol and GSK-159797 are ultra-LABAs that are likely to be introduced into the market before 2010. It is plausible that once-daily dose administration of an LABA will lead to increased convenience for patients, which may also lead to enhancement of adherence, and may have advantages leading to improved overall clinical outcomes in patients with asthma and COPD.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/10 - Malattie dell'Apparato Respiratorio
English
Con Impact Factor ISI
arformoterol; beta adrenergic receptor stimulating agent; bronchodilating agent; budesonide; carmoterol; formoterol; glycopyrronium bromide; gsk 159797; gsk 233705; gsk 685698; indacaterol; leukotriene receptor blocking agent; mometasone furoate; qva 149; salbutamol; salmeterol; theophylline; asthma; binding affinity; bronchodilatation; chronic obstructive lung disease; clinical trial; disease exacerbation; dosage schedule comparison; dose response; drug dosage form comparison; drug dose comparison; drug dose escalation; drug efficacy; drug potency; drug potentiation; drug receptor binding; drug safety; drug sensitivity; drug structure; drug tolerability; human; hyperglycemia; hypokalemia; monotherapy; nonhuman; powder inhaler; review; tachyphylaxis; Adrenergic beta-Agonists; Amphetamines; Animals; Asthma; Bronchodilator Agents; Ethanolamines; Humans; Hydroxyquinolines; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Receptors, Adrenergic, beta-2
Matera, M.G., & Cazzola, M. (2007). Ultra-long-acting beta(2)-adrenoceptor agonists - An emerging therapeutic option for asthma and COPD?. DRUGS, 67(4), 503-515 [10.2165/00003495-200767040-00002].
Matera, M; Cazzola, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/42207
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 43
social impact